Distribution  	Distribution  	 NN	B-NP
of  	of  	 IN	I-NP
primary  	primary  	 JJ	I-NP
immunodeficiency  	immunodeficiency  	 JJ	I-NP
disorders  	disorders  	 NNS	I-NP
diagnosed  	diagnosed  	 VBN	O
in  	in  	 IN	O
a  	a  	 DT	O
tertiary  	tertiary  	 JJ	B-NP
referral  	referral  	 NN	I-NP
center 	center 	 NN	I-NP
, 	, 	 ,	O
Tehran 	Tehran 	 NNP	B-NP
,  	,  	 ,	O
Iran  	Iran  	 NNP	B-NP
( 	( 	 -LRB-	O
2006-2013 	2006-2013 	 NNP	O
)  	)  	 -RRB-	O
Primary  	Primary  	 JJ	B-NP
immunodeficiency  	immunodeficiency  	 JJ	I-NP
disorders  	disorders  	 NNS	I-NP
( 	( 	 -LRB-	O
PID 	PID 	 NNP	B-NP
)  	)  	 -RRB-	O
are  	are  	 VBP	O
a  	a  	 DT	O
group  	group  	 NN	O
of  	of  	 IN	O
hereditary  	hereditary  	 JJ	B-NP
disorders  	disorders  	 NNS	I-NP
characterized  	characterized  	 VBN	O
by  	by  	 IN	O
an  	an  	 DT	O
increased  	increased  	 JJ	O
susceptibility  	susceptibility  	 NN	O
to  	to  	 TO	O
severe  	severe  	 JJ	O
and  	and  	 CC	O
recurrent  	recurrent  	 JJ	O
infections 	infections 	 NNS	O
,  	,  	 ,	O
autoimmunity 	autoimmunity 	 NN	B-NP
,  	,  	 ,	O
lymphoproliferative  	lymphoproliferative  	 JJ	B-NP
disorders 	disorders 	 NNS	I-NP
,  	,  	 ,	O
and  	and  	 CC	O
malignancy 	malignancy 	 NN	B-NP
.  	.  	 .	O
To  	To  	 TO	O
evaluate  	evaluate  	 VB	O
the  	the  	 DT	O
demographic  	demographic  	 JJ	B-NP
and  	and  	 CC	O
clinical  	clinical  	 JJ	B-NP
data  	data  	 NNS	I-NP
of  	of  	 IN	I-NP
PID  	PID  	 NNP	I-NP
patients  	patients  	 NNS	I-NP
diagnosed  	diagnosed  	 VBN	O
in  	in  	 IN	O
a  	a  	 DT	O
referral  	referral  	 JJ	O
pediatric  	pediatric  	 JJ	B-NP
hospital 	hospital 	 NN	I-NP
.  	.  	 .	O
All  	All  	 DT	O
PID  	PID  	 NNP	B-NP
cases  	cases  	 NNS	I-NP
with  	with  	 IN	O
a  	a  	 DT	O
confirmed  	confirmed  	 JJ	O
diagnosis 	diagnosis 	 NN	O
,  	,  	 ,	O
according  	according  	 VBG	O
to  	to  	 TO	O
the  	the  	 DT	O
criteria  	criteria  	 NNS	O
of  	of  	 IN	O
International  	International  	 NNP	O
Union  	Union  	 NNP	O
of  	of  	 IN	O
Immunological  	Immunological  	 NNP	O
Societies 	Societies 	 NNP	O
,  	,  	 ,	O
who  	who  	 WP	O
were  	were  	 VBD	O
referred  	referred  	 VBN	O
to  	to  	 TO	O
the  	the  	 DT	O
Children 	Children 	 NNP	O
's  	's  	 POS	O
Medical  	Medical  	 NNP	O
Center  	Center  	 NNP	O
in  	in  	 IN	O
Tehran 	Tehran 	 NNP	B-NP
,  	,  	 ,	O
Iran 	Iran 	 NNP	B-NP
,  	,  	 ,	O
between  	between  	 IN	O
March  	March  	 NNP	O
2006  	2006  	 CD	O
and  	and  	 CC	O
March  	March  	 NNP	O
2013  	2013  	 CD	O
were  	were  	 VBD	O
enrolled  	enrolled  	 VBN	O
in  	in  	 IN	O
this  	this  	 DT	O
retrospective  	retrospective  	 JJ	B-NP
cohort  	cohort  	 JJ	I-NP
study 	study 	 NN	I-NP
.  	.  	 .	O
Three-hundred  	Three-hundred  	 NNP	O
and  	and  	 CC	O
seven  	seven  	 CD	O
PID  	PID  	 NN	B-NP
patients  	patients  	 NNS	I-NP
were  	were  	 VBD	O
investigated 	investigated 	 VBN	O
.  	.  	 .	O
Predominantly  	Predominantly  	 RB	O
antibody  	antibody  	 JJ	O
deficiencies  	deficiencies  	 NNS	O
were  	were  	 VBD	O
the  	the  	 DT	O
most  	most  	 RBS	O
common  	common  	 JJ	O
group  	group  	 NN	O
of  	of  	 IN	O
PID  	PID  	 NNP	B-NP
observed  	observed  	 VBD	O
in  	in  	 IN	O
118  	118  	 CD	O
cases  	cases  	 NNS	O
( 	( 	 -LRB-	O
38.4 	38.4 	 CD	O
% 	% 	 NN	O
) 	) 	 -RRB-	O
,  	,  	 ,	O
followed  	followed  	 VBN	O
by  	by  	 IN	O
the  	the  	 DT	O
well-defined  	well-defined  	 JJ	O
syndromes  	syndromes  	 NN	O
with  	with  	 IN	O
immunodeficiency  	immunodeficiency  	 NN	B-NP
in  	in  	 IN	O
52  	52  	 CD	O
( 	( 	 -LRB-	O
16.9 	16.9 	 CD	O
% 	% 	 NN	O
) 	) 	 -RRB-	O
,  	,  	 ,	O
congenital  	congenital  	 JJ	B-NP
defects  	defects  	 NNS	I-NP
of  	of  	 IN	O
phagocyte  	phagocyte  	 NN	O
in  	in  	 IN	O
45  	45  	 CD	O
( 	( 	 -LRB-	O
14.7 	14.7 	 CD	O
% 	% 	 NN	O
) 	) 	 -RRB-	O
,  	,  	 ,	O
combined  	combined  	 JJ	O
immunodeficiencies  	immunodeficiencies  	 NN	B-NP
in  	in  	 IN	O
36  	36  	 CD	O
( 	( 	 -LRB-	O
11.7 	11.7 	 CD	O
% 	% 	 NN	O
) 	) 	 -RRB-	O
,  	,  	 ,	O
autoinflammatory  	autoinflammatory  	 JJ	B-NP
disorders  	disorders  	 NNS	I-NP
in  	in  	 IN	O
34  	34  	 CD	O
( 	( 	 -LRB-	O
11.4 	11.4 	 CD	O
% 	% 	 NN	O
) 	) 	 -RRB-	O
,  	,  	 ,	O
immune  	immune  	 JJ	O
dysregulation  	dysregulation  	 NN	B-NP
in  	in  	 IN	O
11  	11  	 CD	O
( 	( 	 -LRB-	O
3.6 	3.6 	 CD	O
% 	% 	 NN	O
) 	) 	 -RRB-	O
,  	,  	 ,	O
complement  	complement  	 JJ	B-NP
deficiencies  	deficiencies  	 NNS	I-NP
in  	in  	 IN	O
7  	7  	 CD	O
( 	( 	 -LRB-	O
2.3 	2.3 	 CD	O
% 	% 	 NN	O
) 	) 	 -RRB-	O
,  	,  	 ,	O
and  	and  	 CC	O
defects  	defects  	 NNS	O
in  	in  	 IN	O
innate  	innate  	 JJ	O
immunity  	immunity  	 NN	O
in  	in  	 IN	O
3  	3  	 CD	O
( 	( 	 -LRB-	O
1 	1 	 CD	O
% 	% 	 NN	O
) 	) 	 -RRB-	O
.  	.  	 .	O
Selective  	Selective  	 JJ	B-NP
IgA  	IgA  	 JJ	I-NP
deficiency  	deficiency  	 NN	I-NP
was  	was  	 VBD	O
the  	the  	 DT	O
most  	most  	 RBS	O
prevalent  	prevalent  	 JJ	O
disorder  	disorder  	 NN	O
which  	which  	 WDT	O
affected  	affected  	 VBD	O
46  	46  	 CD	O
individuals  	individuals  	 NNS	O
( 	( 	 -LRB-	O
14.9 	14.9 	 CD	O
% 	% 	 NN	O
) 	) 	 -RRB-	O
.  	.  	 .	O
The  	The  	 DT	O
median  	median  	 JJ	B-NP
diagnostic  	diagnostic  	 JJ	I-NP
delay  	delay  	 NN	I-NP
was  	was  	 VBD	O
15  	15  	 CD	O
months 	months 	 NNS	O
.  	.  	 .	O
Increased  	Increased  	 JJ	O
awareness  	awareness  	 NN	O
and  	and  	 CC	O
availability  	availability  	 NN	O
of  	of  	 IN	O
diagnostic  	diagnostic  	 JJ	B-NP
tests  	tests  	 NNS	I-NP
could  	could  	 MD	O
result  	result  	 VB	O
in  	in  	 IN	O
the  	the  	 DT	O
better  	better  	 JJR	O
recognition  	recognition  	 NN	O
of  	of  	 IN	O
more  	more  	 RBR	O
undiagnosed  	undiagnosed  	 JJ	O
PID  	PID  	 NN	B-NP
cases  	cases  	 NNS	I-NP
and  	and  	 CC	O
a  	a  	 DT	O
decrease  	decrease  	 NN	O
in  	in  	 IN	O
diagnostic  	diagnostic  	 JJ	B-NP
delay 	delay 	 NN	I-NP
.  	.  	 .	O
